NEFL monoclonal antibody, clone SPM204
- Known as:
- NEFL mab (anti-), clonality SPM204
- Catalog number:
- MAB7029
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- NEFL monoclonal antibody clone SPM204
Related genes to: NEFL monoclonal antibody, clone SPM204
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL monoclonal antibody, clone SPM204
Related articles to: NEFL monoclonal antibody, clone SPM204
- Blood-based biomarkers are increasingly recognized as promising tools for the diagnosis and monitoring of neurodegenerative diseases, offering a minimally invasive alternative to cerebrospinal fluid (CSF) testing. We evaluated the analytical performance and clinical utility of the Olink Target 48 Neurodegeneration panel, a novel multiplex proteomic platform based on the proximity extension assay (PEA) technology, in a large, clinically diverse dementia cohort. - Source: PubMed
Publication date: 2026/07/11
Bentivenga Giuseppe MarioMammana AngelaBaiardi SimoneVittoriosi EricaMastrangelo AndreaRuggeri EdoardoVargiu Claudia MarinaPolischi BarbaraStanzani-Maserati MichelangeloRizzo GiovanniPantieri RobertaRaggi AlbertoCapellari SabinaParchi Piero - Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are promising multiple sclerosis (MS) biomarkers, but biological confounding and inter-assay variability limit real-world use. We assessed whether Z score normalisation enables platform-agnostic monitoring in people with MS (pwMS) under ocrelizumab, and which early timepoint best stratifies subsequent biomarker trajectories. - Source: PubMed
Publication date: 2026/07/10
Inojosa HernanMasanneck LarsAkgün KatjaHagler RamonaMeuth Sven GOtto CarolinSchindler PatrickSchulze-Bosse KarinKuhle JensBenkert PascalRuprecht KlemensPawlitzki MarcZiemssen Tjalf - Minimal hepatic encephalopathy (MHE) is an underdiagnosed complication of liver cirrhosis, associated with progression to overt hepatic encephalopathy (HE). The Portosystemic Hepatic Encephalopathy Score (PHES) is the recommended diagnostic standard, but its use is hindered by resource constraints and limited accuracy. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are released during neuroaxonal and astrocyte injury and may serve as HE-biomarkers. We investigated NfL and GFAP in cerebrospinal fluid (CSF) and serum across the spectrum of HE and assessed their correlation and diagnostic performance. - Source: PubMed
Jonasson EliseGrønkjær Lea LJacobsen Birgitte GOlsen Dorte AWernberg Charlotte WKuhle JensMadsen Jonna SSejbaek TobiasLauridsen Mette M - Advances in ultrasensitive assay techniques have enabled precise quantification of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP), highlighting their potential as dynamic biomarkers for detecting neuroaxonal injury, disease activity and progression in multiple sclerosis (MS). In the NeuroFilMS study, sNfL is being investigated prospectively as a prognostic biomarker for clinical and radiological disease activity in relapsing MS, while sGFAP is retrospectively explored as a marker of disease progression. The aim is to assess whether longitudinal monitoring of sNfL can inform diagnostic and therapeutic decisions in the treatment of people with MS (pwMS) and whether retrospective sGFAP measurements provide additional insights into disease progression. The study additionally aims to evaluate the comparability of different assay methods. - Source: PubMed
Publication date: 2026/07/08
Rust RebekkaSamadzadeh SaraRöper Anna-LenaStahmann AlexanderSchindler PatrickNeumaier MichaelRausch Hans-WernerSchirmer LucasKuhle JensTumani HayrettinPaul FriedemannBahr Lina Samira - Post-COVID syndrome (PCS) is characterized by persistent heterogeneous symptoms after SARS-CoV-2 infection, yet objective biomarkers for symptom severity and longitudinal disease trajectories remain limited. We aimed to characterize muscle function over time in PCS and examine its relationship with symptom burden and neuroaxonal injury markers. - Source: PubMed
Publication date: 2026/07/07
Wunderle MichaelRibeiro AndreaLethen IsabelleSchmaderer ChristophWallraven Timon